Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release attached as Exhibit 99.1 about a product approval. The document is short (1301 characters) and primarily serves as a regulatory filing to inform the SEC and investors about the press release. It does not contain financial statements, detailed financial data, or management discussion. It is not an annual or interim report, earnings release, or any other detailed financial or governance report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 6-K that do not fit other categories.
2025-12-29 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Sanofi, which is a report of a foreign private issuer under the SEC Exchange Act. It references a press release dated December 24, 2025, providing an update on a regulatory submission. The document is short (1321 characters) and primarily serves to announce the attached press release rather than containing substantive financial data or detailed report content. It does not contain financial statements or detailed analysis, nor is it a certification or voting result. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-12-29 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by Sanofi, a foreign private issuer. Form 6-K is used to report material information that is not required to be filed on Forms 20-F or 40-F, often including press releases or other announcements. The text states that the Form 6-K contains a press release issued by Sanofi dated December 24, 2025, incorporated by reference as Exhibit 99.1. The document itself is short (1886 characters) and primarily serves to announce the press release rather than containing substantive financial data or detailed reports. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K filings reporting press releases or other announcements.
2025-12-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains references to press releases attached as exhibits, which are typical for 6-K filings that provide updates or announcements but do not contain comprehensive financial statements or detailed reports. The document length is short (1466 characters), and it mainly announces press releases rather than providing full financial data or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-12-23 English
Sanofi: Information concerning the total number of voting rights and shares - November 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document provides the total number of voting rights and shares for Sanofi, citing Article L. 233-8 II of the French Commercial Code. This is a standard regulatory disclosure regarding share capital and voting rights, which falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-22 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025
Share Issue/Capital Change Classification · 95% confidence The document is a standard French regulatory disclosure regarding the total number of voting rights and shares, as required by Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation. This type of filing is a recurring regulatory requirement for listed companies in France to update the market on share capital structure. Since it does not fit into specific categories like 'Share Issue' (SHA) or 'Transaction in Own Shares' (POS) but is a mandatory regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2025-12-22 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.